IMMUNOLOGICAL PRECONDITIONS OF CONVERSION FROM NATALIZUMAB TO FINGOLIMOD

Медицинский совет

M. B. Paschenkov¹  M. V. Melnikov¹  E. V. Popova²  A. N. Boyko³ 

[1] Clinical Immunology Laboratory of State National Center Immunology Center of the Federal Medical and Biological Agency, Moscow;Interregional Department of Disseminated Sclerosis (Municipal Clinical Hospital No. 24 of the Moscow Healthcare Department)Pirogov Russian National Research Medical University, Moscow;Pirogov Russian National Research Medical University, Moscow;

关键词: relapsing-remitting multiple sclerosis;    natalizumab;    fingolimod;    cd4+ t-cells;    th17-cells;    interleukin-17;   

DOI  :  10.21518/2079-701X-2017-0-80-83

来源: DOAJ

【 摘 要 】

This article presents the results of the immunological profile of CD4+ T cells and Th17 cells and production of interleukin-17 (IL-17) in two groups of patients receiving treatment natalizumab and fingolimod. The results can underpin the justification for the preferred transfer of patients with relapsing-remitting multiple sclerosis after treatment by natalizumab to fingolimod.

【 授权许可】

Unknown